Sertraline Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
Therapeutic Class
Antidepressant
Subclass
Selective Serotonin Reuptake Inhibitor (SSRI)
Speciality
Psychiatry
Schedule (India)
Schedule H
Routes
Oral
Formulations
• Tablets: 25 mg, 50 mg, 100 mg
¯ Oral concentrate/solution: NOT AVAILABLE in India
Adult indications
Indications and dosing
Primary Indications (Approved / Standard in India)
1. Major Depressive Disorder (MDD) — Adults
| Parameter | Details |
|---|---|
| Unidentified | 50 mg once daily (morning or evening with food) |
| Unidentified | Increase by 50 mg/day at intervals of ≥1 week if inadequate response |
|
Usual maintenance dose
|
50–100 mg once daily |
|
Maximum dose
|
200 mg/day |
Clinical notes:
• Onset of antidepressant effect: 2–4 weeks
• Trial duration: Minimum 6–8 weeks at therapeutic dose before declaring treatment failure
• Long-term therapy: Continue for 6–12 months after remission if first episode; longer (≥2 years) if recurrent depression
• Taper gradually when discontinuing (reduce by 25–50 mg every 1–2 weeks) to minimize withdrawal symptoms
• Onset of antidepressant effect: 2–4 weeks
• Trial duration: Minimum 6–8 weeks at therapeutic dose before declaring treatment failure
• Long-term therapy: Continue for 6–12 months after remission if first episode; longer (≥2 years) if recurrent depression
• Taper gradually when discontinuing (reduce by 25–50 mg every 1–2 weeks) to minimize withdrawal symptoms
2. Obsessive-Compulsive Disorder (OCD) — Adults
| Parameter | Details |
|---|---|
|
Starting dose
|
50 mg once daily |
|
Titration
|
Increase in 50 mg increments at weekly intervals based on response |
|
Usual maintenance dose
|
100–200 mg/day |
|
Maximum dose
|
200 mg/day |
Clinical notes:
• Higher doses often required for OCD compared to depression
• Response may be delayed; trial for at least 10–12 weeks at adequate dose
• Combine with cognitive-behavioural therapy (CBT) for optimal outcomes
• Higher doses often required for OCD compared to depression
• Response may be delayed; trial for at least 10–12 weeks at adequate dose
• Combine with cognitive-behavioural therapy (CBT) for optimal outcomes
3. Panic Disorder — Adults
| Parameter | Details |
|---|---|
|
Starting dose
|
25 mg once daily × 1 week (to reduce activation/anxiety), then increase to 50 mg |
|
Titration
|
Increase in increments of 25–50 mg/day at intervals of ≥1 week |
|
Usual effective dose
|
100–150 mg/day |
|
Maximum dose
|
200 mg/day |
Clinical notes:
• Lower starting dose (25 mg) reduces early activation symptoms (jitteriness, anxiety, insomnia)
• Full response may take 8–12 weeks
• Continue for at least 12–24 months after achieving remission
• Lower starting dose (25 mg) reduces early activation symptoms (jitteriness, anxiety, insomnia)
• Full response may take 8–12 weeks
• Continue for at least 12–24 months after achieving remission
4. Post-Traumatic Stress Disorder (PTSD) — Adults
| Parameter | Details |
|---|---|
|
Starting dose
|
25–50 mg once daily |
|
Titration
|
Increase by 25–50 mg/week based on tolerability and response |
|
Usual maintenance dose
|
100–150 mg/day |
|
Maximum dose
|
200 mg/day |
Clinical notes:
• Evidence-based use per Indian psychiatric practice guidelines
• Combine with trauma-focused psychotherapy
• Evidence-based use per Indian psychiatric practice guidelines
• Combine with trauma-focused psychotherapy
Secondary Indications — Adults (Off-label)
1. Social Anxiety Disorder (Social Phobia) — OFF-LABEL
• Indication: Social anxiety disorder / social phobia
• Starting dose: 25–50 mg once daily
• Titration: Slow increments of 25–50 mg every 1–2 weeks
• Usual effective dose: 50–100 mg/day
• Maximum dose: 200 mg/day (rarely required)
• Duration: Long-term therapy usually required
• Specialist guidance: Psychiatrist consultation recommended
• Evidence basis: International RCTs; widely used in Indian psychiatric practice though not formally CDSCO-approved for this indication
• Starting dose: 25–50 mg once daily
• Titration: Slow increments of 25–50 mg every 1–2 weeks
• Usual effective dose: 50–100 mg/day
• Maximum dose: 200 mg/day (rarely required)
• Duration: Long-term therapy usually required
• Specialist guidance: Psychiatrist consultation recommended
• Evidence basis: International RCTs; widely used in Indian psychiatric practice though not formally CDSCO-approved for this indication
2. Premenstrual Dysphoric Disorder (PMDD) — OFF-LABEL
• Indication: Severe premenstrual mood symptoms meeting PMDD criteria
• Dose: 50–100 mg/day either:
– Continuous (daily) dosing, OR
– Luteal phase dosing (start 14 days before expected menses, stop on day 1 of menses)
• Specialist only: Gynecology or psychiatry consultation required
• Evidence basis: International RCTs; limited use in Indian specialist practice
• Clearly marked OFF-LABEL in patient records
• Dose: 50–100 mg/day either:
– Continuous (daily) dosing, OR
– Luteal phase dosing (start 14 days before expected menses, stop on day 1 of menses)
• Specialist only: Gynecology or psychiatry consultation required
• Evidence basis: International RCTs; limited use in Indian specialist practice
• Clearly marked OFF-LABEL in patient records
3. Generalized Anxiety Disorder (GAD) — OFF-LABEL
• Indication: GAD not responding to first-line agents or when comorbid depression present
• Starting dose: 25–50 mg/day
• Titration: Increase by 25–50 mg every 1–2 weeks
• Usual maintenance dose: 50–100 mg/day
• Maximum dose: 200 mg/day
• Evidence basis: Extension from approved anxiety disorders; Indian psychiatric practice
• Note: Escitalopram has more direct evidence for GAD in India
• Starting dose: 25–50 mg/day
• Titration: Increase by 25–50 mg every 1–2 weeks
• Usual maintenance dose: 50–100 mg/day
• Maximum dose: 200 mg/day
• Evidence basis: Extension from approved anxiety disorders; Indian psychiatric practice
• Note: Escitalopram has more direct evidence for GAD in India
Paediatric indications
PAEDIATRIC DOSING (Specialist Only)
⚠️️use only under paediatric psychiatry or child neurology supervision
Primary Indications (Approved / Standard in India)
1. Obsessive-Compulsive Disorder (OCD) — Age ≥6 years
Children 6–12 years:
| Parameter | Details |
|---|---|
|
Starting dose
|
25 mg once daily |
|
Titration
|
Increase by 25 mg/day at intervals of ≥1 week based on response and tolerability |
|
Usual maintenance dose
|
50–100 mg/day |
|
Maximum dose
|
200 mg/day |
Adolescents ≥13 years:
| Parameter | Details |
|---|---|
|
Starting dose
|
50 mg once daily |
|
Titration
|
Increase in 50 mg increments at weekly intervals |
|
Usual maintenance dose
|
100–150 mg/day |
|
Maximum dose
|
200 mg/day |
Safety monitoring in children:
• Weekly monitoring for first 4 weeks, then biweekly for 8 weeks, then monthly
• Monitor for: suicidal ideation, behavioural activation (aggression, irritability, agitation), growth parameters (height, weight), sexual development
• Combine with age-appropriate CBT
• Weekly monitoring for first 4 weeks, then biweekly for 8 weeks, then monthly
• Monitor for: suicidal ideation, behavioural activation (aggression, irritability, agitation), growth parameters (height, weight), sexual development
• Combine with age-appropriate CBT
Secondary Indications — Paediatrics (Off-label)
Paediatric Depression (Age ≥12 years) — OFF-LABEL
• Starting dose: 25–50 mg/day
• Titration: Increase by 25–50 mg every 1–2 weeks based on response
• Usual maintenance dose: 50–100 mg/day
• Maximum dose: 200 mg/day
• Specialist only: Paediatric psychiatrist
• Evidence basis: Limited RCT support; Indian paediatric psychiatry protocols; fluoxetine has stronger paediatric depression evidence
• Clearly marked OFF-LABEL
• Black box warning: Increased risk of suicidal thoughts and behaviour in children and adolescents; close monitoring essential
• Titration: Increase by 25–50 mg every 1–2 weeks based on response
• Usual maintenance dose: 50–100 mg/day
• Maximum dose: 200 mg/day
• Specialist only: Paediatric psychiatrist
• Evidence basis: Limited RCT support; Indian paediatric psychiatry protocols; fluoxetine has stronger paediatric depression evidence
• Clearly marked OFF-LABEL
• Black box warning: Increased risk of suicidal thoughts and behaviour in children and adolescents; close monitoring essential
Age restrictions:
• Not recommended below age 6 years except under paediatric psychiatry specialist supervision with clear rationale
• Below age 12 years for depression: Not recommended; consider psychotherapy first-line
• Not recommended below age 6 years except under paediatric psychiatry specialist supervision with clear rationale
• Below age 12 years for depression: Not recommended; consider psychotherapy first-line
Renal Adjustments
Mild-to-moderate renal impairment (CrCl ≥30 mL/min or eGFR ≥30 mL/min/1.73m²):
• No dose adjustment required
• No dose adjustment required
Severe renal impairment (CrCl <30 mL/min or eGFR <30 mL/min/1.73m²):
• No specific dosing recommendations available
• Use with caution; start at 25 mg/day and titrate slowly
• Monitor closely for adverse effects (sertraline has minimal renal excretion but may accumulate in severe impairment)
• No specific dosing recommendations available
• Use with caution; start at 25 mg/day and titrate slowly
• Monitor closely for adverse effects (sertraline has minimal renal excretion but may accumulate in severe impairment)
Haemodialysis:
• Sertraline is not significantly removed by dialysis
• No specific dosing guidance; monitor clinical response and tolerability
• Consider lower starting dose (25 mg) and slower titration
• Sertraline is not significantly removed by dialysis
• No specific dosing guidance; monitor clinical response and tolerability
• Consider lower starting dose (25 mg) and slower titration
Peritoneal dialysis:
• No specific data; use caution similar to haemodialysis
• No specific data; use caution similar to haemodialysis
Hepatic adjustment
HEPATIC ADJUSTMENT
Mild hepatic impairment (Child-Pugh A):
• No dose adjustment required
• Monitor for increased adverse effects
• No dose adjustment required
• Monitor for increased adverse effects
Moderate hepatic impairment (Child-Pugh B):
• Start at 50% of recommended dose (e.g., 25 mg/day instead of 50 mg)
• Titrate cautiously at longer intervals (every 2 weeks)
• Maximum dose: 100 mg/day (avoid higher doses)
• Monitor liver function periodically
• Start at 50% of recommended dose (e.g., 25 mg/day instead of 50 mg)
• Titrate cautiously at longer intervals (every 2 weeks)
• Maximum dose: 100 mg/day (avoid higher doses)
• Monitor liver function periodically
Severe hepatic impairment (Child-Pugh C):
• Avoid use if possible
• If essential and no alternative: specialist hepatology + psychiatry input required
• Start at 25 mg every other day or 25 mg twice weekly
• Titrate very slowly with close monitoring
• Avoid use if possible
• If essential and no alternative: specialist hepatology + psychiatry input required
• Start at 25 mg every other day or 25 mg twice weekly
• Titrate very slowly with close monitoring
Mechanism: Sertraline undergoes extensive hepatic metabolism; impaired clearance in liver disease increases risk of accumulation and toxicity
Contraindications
CONTRAINDICATIONS
Absolute contraindications:
• Known hypersensitivity to sertraline or any excipients in the formulation
• Concurrent use with monoamine oxidase inhibitors (MAOIs):
– Do not use sertraline within 14 days after stopping an MAOI (risk of serotonin syndrome)
– Do not start an MAOI within 14 days after stopping sertraline (allow washout)
– Includes: phenelzine, tranylcypromine, isocarboxazid (rare in India), selegiline, rasagiline
– Do not use sertraline within 14 days after stopping an MAOI (risk of serotonin syndrome)
– Do not start an MAOI within 14 days after stopping sertraline (allow washout)
– Includes: phenelzine, tranylcypromine, isocarboxazid (rare in India), selegiline, rasagiline
• Concurrent use with pimozide (risk of QT prolongation and torsades de pointes; pharmacokinetic interaction via CYP2D6)
• Concurrent use with linezolid or intravenous methylene blue (potent reversible MAOIs; serotonin syndrome risk)
– Exception: Life-threatening situation requiring linezolid/methylene blue → discontinue sertraline, give linezolid/methylene blue, monitor closely, restart sertraline 24 hours after last dose of linezolid/methylene blue
– Exception: Life-threatening situation requiring linezolid/methylene blue → discontinue sertraline, give linezolid/methylene blue, monitor closely, restart sertraline 24 hours after last dose of linezolid/methylene blue
• Acute intoxication with alcohol, sedatives, hypnotics, or psychotropic drugs
Cautions
CAUTIONS
Use with caution and close monitoring in:
• History of seizures or epilepsy — SSRIs lower seizure threshold (dose-dependent); risk higher with rapid dose escalation or high doses
• Bipolar disorder or history of mania/hypomania — risk of switching to manic episode; ensure mood stabilizer in place before starting SSRI
• Bleeding disorders or concurrent anticoagulation/antiplatelet therapy — SSRIs impair platelet function (inhibit serotonin uptake in platelets); increased risk of GI bleeding, especially with NSAIDs, aspirin, warfarin, clopidogrel
• History of GI bleeding — SSRIs increase risk; consider proton pump inhibitor (PPI) co-prescription if on NSAIDs or anticoagulants
• Angle-closure glaucoma — SSRIs can cause pupillary dilation (rare); risk of acute angle-closure attack in predisposed individuals (shallow anterior chamber)
• Hyponatremia / SIADH risk factors — elderly, volume-depleted, diuretic use, chronic kidney disease, hypothyroidism; monitor sodium especially first 4 weeks
• Cardiac disease — sertraline has low cardiac risk among SSRIs but caution in recent MI, unstable angina, significant arrhythmias, congenital long QT syndrome
• Hepatic impairment — see Hepatic Adjustment section
• Renal impairment — see Renal Adjustment section
• Diabetes mellitus — SSRIs may affect glycemic control (usually improve depression-related hyperglycemia, but monitor)
• Suicidal ideation / high suicide risk — close monitoring essential, especially:
– First 4 weeks of treatment
– After dose changes
– In adolescents and young adults (<25 years)
– Provide emergency contact information; involve family in monitoring
– First 4 weeks of treatment
– After dose changes
– In adolescents and young adults (<25 years)
– Provide emergency contact information; involve family in monitoring
• Concomitant use of serotonergic drugs — tramadol, triptans, tryptophan supplements, St. John's wort, other antidepressants (risk of serotonin syndrome)
• Alcohol use — advise patients to avoid alcohol (potentiates CNS effects)
• History of sexual dysfunction — SSRIs commonly cause sexual side effects; discuss proactively
Pregnancy
PREGNANCY
| Aspect | Details |
|---|---|
|
Risk category
|
Australian Category C: Drugs which have caused or may be suspected of causing harmful effects on the human fetus or neonate without causing malformations. US FDA pregnancy categories discontinued; sertraline historically Category C. |
|
Overall safety
|
Generally considered low risk and preferred SSRI in pregnancy when antidepressant treatment required. Untreated maternal depression poses significant risks to mother and fetus.
|
|
Indian obstetric practice
|
Preferred SSRI for antenatal depression and anxiety disorders in Indian obstetric psychiatry practice. Fluoxetine and sertraline are most studied SSRIs in pregnancy.
|
|
When to use
|
Use when benefit outweighs risk: • Moderate-to-severe depression/anxiety affecting maternal functioning • History of severe depression with high relapse risk • Suicidal ideation • Previous good response to sertraline • Patient preference after informed discussion |
|
Preferred alternatives
|
Non-pharmacologic first-line: Psychotherapy (CBT, interpersonal therapy) for mild-to-moderate depression. Pharmacologic if needed: Sertraline or fluoxetine preferred among SSRIs. Avoid: Paroxetine (cardiac malformations risk).
|
|
Timing considerations
|
First trimester: Limited data suggest no increased major malformation risk, though some studies show small absolute risk increase (controversy). Third trimester: Risk of neonatal adaptation syndrome (see monitoring). Postpartum: Continue if stable; benefits of treatment usually outweigh risks.
|
|
Monitoring — Maternal
|
• Mental health status (depression scores, suicidal ideation) at each visit • Blood pressure (rare hypertensive effects) • Weight gain • Liver function if baseline impairment |
|
Monitoring — Fetal/Neonatal
|
• Fetal growth and movements (routine antenatal care) • Neonatal adaptation syndrome if used in late 3rd trimester (20–30% neonates exposed): jitteriness, tremor, irritability, weak cry, feeding difficulties, respiratory distress, hypoglycemia, hypotonia or hypertonia; usually self-limited, resolves within 2 weeks • Persistent pulmonary hypertension of newborn (PPHN): rare (absolute risk <1%) but serious; risk slightly increased with late-pregnancy SSRI exposure; monitor newborn respiratory status • Admit neonate to observation if mother on sertraline in last trimester; pediatric consultation
|
|
Lactation transition
|
Sertraline compatible with breastfeeding (see Lactation section); continue postpartum if effective. |
|
Counseling points
|
• Discuss risks vs. benefits; shared decision-making • Untreated depression risks: poor prenatal care, substance use, preterm birth, low birth weight, postpartum depression • Document informed consent • Coordinate care: psychiatry + obstetrics |
Lactation
| Aspect | Details |
|---|---|
|
Compatibility
|
Compatible with breastfeeding — sertraline is preferred SSRI during lactation
|
|
Drug levels in milk
|
Low to very low — sertraline and its metabolite (desmethylsertraline) have low milk/plasma ratios (approximately 1:2). Relative infant dose (RID): 0.4–2.2% of maternal weight-adjusted dose (well below 10% safety threshold). Infant serum levels usually undetectable or very low.
|
|
Preferred SSRI in lactation
|
Yes — sertraline, paroxetine, and escitalopram have lowest infant exposure among SSRIs. Sertraline particularly favored due to extensive safety data.
|
|
Preferred alternatives
|
Non-pharmacologic: Psychotherapy (CBT) for mild-to-moderate postpartum depression/anxiety. Pharmacologic if SSRI needed: Sertraline remains first choice. Paroxetine also low in milk but has other drawbacks (weight gain, withdrawal).
|
|
Timing of dosing
|
Administer immediately after breastfeeding (typically evening feed) to minimize infant exposure at subsequent feeds, though practical benefit minimal given long half-life.
|
|
Infant monitoring
|
• Feeding: Assess adequacy of breastfeeding, infant satisfaction after feeds • Weight gain: Monitor growth parameters at routine pediatric visits (weekly first month, then monthly) • Sedation / CNS effects: Watch for excessive drowsiness, lethargy, poor tone (very rare with sertraline) • Irritability / agitation: Rarely reported; may be difficult to distinguish from normal infant behavior • GI symptoms: Rare reports of colic, loose stools • If any concerns: Measure infant serum sertraline level (usually undetectable); consult pediatrician
|
|
What to tell mothers
|
• Benefits of breastfeeding (nutrition, bonding, maternal mental health) generally outweigh very low drug exposure • Sertraline has been studied extensively in breastfeeding with reassuring data • Observe baby for unusual sleepiness, poor feeding, or irritability and report to pediatrician • Do not stop sertraline abruptly without medical advice (maternal withdrawal symptoms, relapse risk) |
|
LactMed / WHO status
|
LactMed (NIH): Sertraline is acceptable during breastfeeding; preferred SSRI. WHO: Compatible with breastfeeding. |
Elderly
ELDERLY
Starting dose:
• 25 mg once daily (50% of standard adult starting dose)
• Elderly more sensitive to adverse effects (CNS, GI, hyponatremia)
• 25 mg once daily (50% of standard adult starting dose)
• Elderly more sensitive to adverse effects (CNS, GI, hyponatremia)
Titration:
• Increase slowly: 25 mg increments every 2 weeks (slower than standard weekly titration)
• Assess response and tolerability at each step
• Many elderly patients respond to lower doses (25–50 mg/day)
• Increase slowly: 25 mg increments every 2 weeks (slower than standard weekly titration)
• Assess response and tolerability at each step
• Many elderly patients respond to lower doses (25–50 mg/day)
Usual maintenance dose:
• 25–100 mg/day (often lower end of range sufficient)
• 25–100 mg/day (often lower end of range sufficient)
Maximum dose:
• Generally, limit to 150 mg/day in elderly (avoid 200 mg unless compelling indication and good tolerability)
• Generally, limit to 150 mg/day in elderly (avoid 200 mg unless compelling indication and good tolerability)
Extra risks in elderly:
• Hyponatremia / SIADH: Most common serious adverse effect in elderly on SSRIs
– Risk factors: age >65 years, female, low body weight, diuretic use, baseline low sodium
– Monitor serum sodium at baseline, 2 weeks, 4 weeks, then as clinically indicated
– Symptoms: confusion, headache, lethargy, falls, seizures
– Management: Stop sertraline, fluid restriction, specialist input; consider switching to mirtazapine if antidepressant still needed
– Risk factors: age >65 years, female, low body weight, diuretic use, baseline low sodium
– Monitor serum sodium at baseline, 2 weeks, 4 weeks, then as clinically indicated
– Symptoms: confusion, headache, lethargy, falls, seizures
– Management: Stop sertraline, fluid restriction, specialist input; consider switching to mirtazapine if antidepressant still needed
• Falls: Increased risk due to:
– Dizziness, orthostatic hypotension (rare with sertraline but possible)
– Hyponatremia causing confusion
– Sedation (especially if combined with benzodiazepines)
– Advise fall precautions; review polypharmacy
– Dizziness, orthostatic hypotension (rare with sertraline but possible)
– Hyponatremia causing confusion
– Sedation (especially if combined with benzodiazepines)
– Advise fall precautions; review polypharmacy
• Cognitive impairment: Ensure adequate trial of antidepressant before attributing cognitive symptoms to depression vs. dementia; SSRIs generally do not worsen cognition but severe hyponatremia can mimic dementia
• Bleeding risk: Higher baseline risk of GI bleeding in elderly; further increased with SSRIs + NSAIDs / aspirin / anticoagulants
– Consider PPI co-prescription if on antiplatelet / anticoagulant therapy
– Consider PPI co-prescription if on antiplatelet / anticoagulant therapy
• Drug interactions: Polypharmacy common; review medication list carefully (see interactions sections)
• Renal and hepatic function: Age-related decline; monitor renal function (eGFR) and hepatic function; adjust dose if impaired (see respective sections)
Monitoring in elderly:
• Baseline: Sodium, renal function, liver function, medications review, falls risk
• 2 weeks: Sodium, clinical response, tolerability, suicidal ideation
• 4 weeks: Sodium, clinical response
• Ongoing: Sodium if symptoms, clinical response monthly until stable, then every 3–6 months
• Baseline: Sodium, renal function, liver function, medications review, falls risk
• 2 weeks: Sodium, clinical response, tolerability, suicidal ideation
• 4 weeks: Sodium, clinical response
• Ongoing: Sodium if symptoms, clinical response monthly until stable, then every 3–6 months
Major drug interactions
MAJOR DRUG INTERACTIONS
Interactions requiring avoidance or significant caution:
1. Monoamine Oxidase Inhibitors (MAOIs)
Drugs: Phenelzine, tranylcypromine, isocarboxazid (rare in India), selegiline, rasagiline, linezolid, intravenous methylene blue
Mechanism: Combined serotonin reuptake inhibition + MAO inhibition → serotonin syndrome (excess serotonergic activity)
Risk: Life-threatening serotonin syndrome (hyperthermia, rigidity, myoclonus, autonomic instability, altered consciousness, seizures, death)
Management:CONTRAINDICATED
• Do not use sertraline within 14 days after stopping MAOI
• Do not start MAOI within 14 days after stopping sertraline
• Exception for linezolid/methylene blue: see Contraindications section
• Do not use sertraline within 14 days after stopping MAOI
• Do not start MAOI within 14 days after stopping sertraline
• Exception for linezolid/methylene blue: see Contraindications section
2. Pimozide
Mechanism: Sertraline inhibits CYP2D6, reducing pimozide metabolism; both drugs prolong QT interval → additive risk
Risk: QT prolongation, torsades de pointes, sudden cardiac death
Management:CONTRAINDICATED — do not use together
3. Serotonergic Drugs (Serotonin Syndrome Risk)
Drugs:
• Tramadol (analgesic with serotonergic activity)
• Triptans (sumatriptan, rizatriptan, etc. — migraine therapy)
• Tryptophan supplements
• St. John's wort (hypericum)
• Other antidepressants (SNRIs: venlafaxine, duloxetine; TCAs; mirtazapine; MAOIs)
• Lithium
• Fentanyl (high doses)
• Dextromethorphan (cough suppressant, high doses)
• Amphetamines, methylphenidate
• Tramadol (analgesic with serotonergic activity)
• Triptans (sumatriptan, rizatriptan, etc. — migraine therapy)
• Tryptophan supplements
• St. John's wort (hypericum)
• Other antidepressants (SNRIs: venlafaxine, duloxetine; TCAs; mirtazapine; MAOIs)
• Lithium
• Fentanyl (high doses)
• Dextromethorphan (cough suppressant, high doses)
• Amphetamines, methylphenidate
Mechanism: Additive serotonergic activity → serotonin syndrome
Risk: Serotonin syndrome (mild: tremor, diarrhea, sweating; severe: hyperthermia, rigidity, seizures, rhabdomyolysis, death)
Management:
• Avoid combination if possible
• If essential (e.g., triptan for migraine in patient on sertraline):
– Use lowest effective triptan dose
– Monitor closely for serotonin syndrome (especially first dose)
– Educate patient on symptoms: agitation, confusion, rapid heart rate, dilated pupils, tremor, sweating, diarrhea, muscle rigidity — seek immediate care if occurs
• Tramadol: Consider alternative analgesic (paracetamol, NSAIDs, opioids without serotonergic activity); if tramadol essential, use lowest dose and monitor
• Lithium: Used together in refractory depression (augmentation strategy) but requires specialist psychiatry supervision and therapeutic lithium monitoring
• Avoid combination if possible
• If essential (e.g., triptan for migraine in patient on sertraline):
– Use lowest effective triptan dose
– Monitor closely for serotonin syndrome (especially first dose)
– Educate patient on symptoms: agitation, confusion, rapid heart rate, dilated pupils, tremor, sweating, diarrhea, muscle rigidity — seek immediate care if occurs
• Tramadol: Consider alternative analgesic (paracetamol, NSAIDs, opioids without serotonergic activity); if tramadol essential, use lowest dose and monitor
• Lithium: Used together in refractory depression (augmentation strategy) but requires specialist psychiatry supervision and therapeutic lithium monitoring
4. Anticoagulants and Antiplatelet Agents
Drugs: Warfarin, heparin, dabigatran, rivaroxaban, apixaban, aspirin, clopidogrel, prasugrel, ticagrelor
Mechanism: SSRIs inhibit serotonin uptake into platelets → impaired platelet aggregation → increased bleeding risk; additive with anticoagulants/antiplatelets. Sertraline also may inhibit warfarin metabolism (CYP2C9, protein binding displacement) → increased INR.
Risk: Increased risk of bleeding (GI bleeding most common; also intracranial hemorrhage, ecchymoses)
Management:
• Not contraindicated but requires close monitoring
• Warfarin: Check INR more frequently after starting/stopping sertraline or dose changes; may need warfarin dose adjustment
• Aspirin / clopidogrel: If used for cardiovascular indications (post-MI, post-stent), benefits usually outweigh bleeding risk; continue but:
– Monitor for bleeding (GI symptoms, bruising, hematuria)
– Consider PPI co-prescription (omeprazole, pantoprazole) to reduce GI bleeding risk
– Educate patient on bleeding warning signs
• NSAIDs: See Moderate Interactions; similar bleeding risk
• Not contraindicated but requires close monitoring
• Warfarin: Check INR more frequently after starting/stopping sertraline or dose changes; may need warfarin dose adjustment
• Aspirin / clopidogrel: If used for cardiovascular indications (post-MI, post-stent), benefits usually outweigh bleeding risk; continue but:
– Monitor for bleeding (GI symptoms, bruising, hematuria)
– Consider PPI co-prescription (omeprazole, pantoprazole) to reduce GI bleeding risk
– Educate patient on bleeding warning signs
• NSAIDs: See Moderate Interactions; similar bleeding risk
5. QT-Prolonging Drugs (Additive QT Prolongation)
Drugs: Amiodarone, sotalol, quinidine, procainamide, haloperidol, droperidol, chlorpromazine, methadone, ondansetron (high dose IV), azithromycin, clarithromycin, fluoroquinolones (moxifloxacin), antifungals (fluconazole, ketoconazole)
Mechanism: Sertraline has low intrinsic QT prolongation risk (less than citalopram, escitalopram) but at high doses (>200 mg) or in predisposed patients (electrolyte abnormalities, cardiac disease, genetic long QT), risk exists; additive with other QT-prolonging drugs
Risk: QT prolongation → torsades de pointes (polymorphic ventricular tachycardia)
Management:
• Use with caution; avoid high-dose sertraline (>150 mg) if on QT-prolonging drug
• Baseline ECG if multiple risk factors or on known QT-prolonging drug
• Correct electrolytes (K+, Mg2+, Ca2+) before and during therapy
• Monitor ECG if symptoms (palpitations, syncope, presyncope)
• Consider alternative antidepressant with lower QT risk (mirtazapine, bupropion — not available in India) or alternative for the other QT-prolonging drug if feasible
• Use with caution; avoid high-dose sertraline (>150 mg) if on QT-prolonging drug
• Baseline ECG if multiple risk factors or on known QT-prolonging drug
• Correct electrolytes (K+, Mg2+, Ca2+) before and during therapy
• Monitor ECG if symptoms (palpitations, syncope, presyncope)
• Consider alternative antidepressant with lower QT risk (mirtazapine, bupropion — not available in India) or alternative for the other QT-prolonging drug if feasible
6. CYP2D6 Substrates with Narrow Therapeutic Index
Drugs: Metoprolol, propafenone, flecainide, thioridazine (rarely used), risperidone, aripiprazole, atomoxetine (not available in India), codeine, tamoxifen
Mechanism: Sertraline is a moderate inhibitor of CYP2D6 → reduces metabolism of CYP2D6 substrates → increased plasma levels → toxicity risk
Risk: Depends on drug:
• Beta-blockers (metoprolol): Excessive bradycardia, hypotension, heart block
• Antiarrhythmics (propafenone, flecainide): Proarrhythmia
• Antipsychotics (risperidone, thioridazine): Extrapyramidal symptoms, QT prolongation (thioridazine)
• Tamoxifen: Reduced conversion to active metabolite (endoxifen) → reduced breast cancer efficacy (controversial; avoid if possible in tamoxifen-treated patients)
• Codeine: Reduced conversion to morphine → reduced analgesic efficacy (not a safety issue but efficacy concern)
• Beta-blockers (metoprolol): Excessive bradycardia, hypotension, heart block
• Antiarrhythmics (propafenone, flecainide): Proarrhythmia
• Antipsychotics (risperidone, thioridazine): Extrapyramidal symptoms, QT prolongation (thioridazine)
• Tamoxifen: Reduced conversion to active metabolite (endoxifen) → reduced breast cancer efficacy (controversial; avoid if possible in tamoxifen-treated patients)
• Codeine: Reduced conversion to morphine → reduced analgesic efficacy (not a safety issue but efficacy concern)
Management:
• Metoprolol / propafenone / flecainide: Use alternative SSRI with minimal CYP2D6 inhibition (escitalopram, citalopram) if possible; if sertraline necessary, monitor heart rate, BP, ECG; may need dose reduction of beta-blocker/antiarrhythmic
• Risperidone: Monitor for extrapyramidal symptoms; may need dose reduction
• Tamoxifen:Avoid sertraline in breast cancer patients on tamoxifen; use venlafaxine (hot flashes) or escitalopram (depression) with less CYP2D6 inhibition
• Codeine: Use alternative opioid (morphine, oxycodone, tramadol — though tramadol has serotonin syndrome risk, see above)
• Metoprolol / propafenone / flecainide: Use alternative SSRI with minimal CYP2D6 inhibition (escitalopram, citalopram) if possible; if sertraline necessary, monitor heart rate, BP, ECG; may need dose reduction of beta-blocker/antiarrhythmic
• Risperidone: Monitor for extrapyramidal symptoms; may need dose reduction
• Tamoxifen:Avoid sertraline in breast cancer patients on tamoxifen; use venlafaxine (hot flashes) or escitalopram (depression) with less CYP2D6 inhibition
• Codeine: Use alternative opioid (morphine, oxycodone, tramadol — though tramadol has serotonin syndrome risk, see above)
Moderate drug interactions
MODERATE DRUG INTERACTIONS
Interactions usually manageable with monitoring or minor adjustments:
1. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
Drugs: Ibuprofen, diclofenac, naproxen, aceclofenac, etoricoxib, celecoxib
Mechanism: Additive antiplatelet effect (SSRI + NSAID) → increased GI bleeding risk
Risk: Upper GI bleeding (absolute risk increase ~2–4 per 1000 patient-years)
Management:
• Use together with caution
• Prescribe PPI (omeprazole 20 mg, pantoprazole 40 mg) if NSAID needed chronically
• Use lowest effective NSAID dose for shortest duration
• Consider selective COX-2 inhibitor (celecoxib, etoricoxib) — lower GI risk but still some risk
• Educate patient on GI bleeding symptoms: black stools, hematemesis, severe abdominal pain → seek immediate care
• Prefer alternative analgesic if possible (paracetamol)
• Use together with caution
• Prescribe PPI (omeprazole 20 mg, pantoprazole 40 mg) if NSAID needed chronically
• Use lowest effective NSAID dose for shortest duration
• Consider selective COX-2 inhibitor (celecoxib, etoricoxib) — lower GI risk but still some risk
• Educate patient on GI bleeding symptoms: black stools, hematemesis, severe abdominal pain → seek immediate care
• Prefer alternative analgesic if possible (paracetamol)
2. Benzodiazepines
Drugs: Alprazolam, clonazepam, lorazepam, diazepam
Mechanism: Pharmacodynamic interaction (additive CNS depression); sertraline may inhibit metabolism of some benzodiazepines (CYP3A4 substrates like alprazolam, diazepam — weak inhibition)
Risk: Increased sedation, dizziness, psychomotor impairment, falls (especially elderly)
Management:
• Can be used together (often co-prescribed for anxiety in India)
• Use lowest effective benzodiazepine dose
• Monitor for excessive sedation, especially first 2 weeks
• Taper benzodiazepine gradually once SSRI effect established (4–6 weeks)
• Avoid long-term benzodiazepine use; goal is short-term anxiolytic bridge while SSRI takes effect
• Can be used together (often co-prescribed for anxiety in India)
• Use lowest effective benzodiazepine dose
• Monitor for excessive sedation, especially first 2 weeks
• Taper benzodiazepine gradually once SSRI effect established (4–6 weeks)
• Avoid long-term benzodiazepine use; goal is short-term anxiolytic bridge while SSRI takes effect
3. Antiepileptic Drugs (Enzyme Inducers)
Drugs: Phenytoin, carbamazepine, phenobarbital, primidone
Mechanism: CYP enzyme induction (CYP3A4, CYP2C19, others) → increased sertraline metabolism → reduced sertraline levels → potential loss of efficacy
Risk: Treatment failure, depression relapse
Management:
• Monitor clinical response closely
• May need higher sertraline dose (titrate to 150–200 mg or higher if tolerated and needed)
• Check sertraline levels if available (not routinely available in India; use clinical response as guide)
• Consider alternative antidepressant less affected by enzyme induction (e.g., mirtazapine) if treatment failure despite dose increase
• Monitor clinical response closely
• May need higher sertraline dose (titrate to 150–200 mg or higher if tolerated and needed)
• Check sertraline levels if available (not routinely available in India; use clinical response as guide)
• Consider alternative antidepressant less affected by enzyme induction (e.g., mirtazapine) if treatment failure despite dose increase
Note: Valproate, lamotrigine, levetiracetam do not significantly affect sertraline levels (no enzyme induction)
4. Rifampicin (Rifampin)
Mechanism: Potent CYP enzyme inducer → markedly increases sertraline metabolism → reduced sertraline levels
Risk: Loss of antidepressant efficacy during TB treatment
Management:
• Anticipate need for higher sertraline dose during rifampicin co-administration
• Monitor depression symptoms closely
• May need to double sertraline dose or more (titrate based on response)
• Consider alternative antidepressant (e.g., mirtazapine, escitalopram — though all affected to some degree)
• After stopping rifampicin: gradually reduce sertraline dose back to pre-rifampicin level over 2–4 weeks (rifampicin enzyme induction wears off over ~2 weeks)
• Anticipate need for higher sertraline dose during rifampicin co-administration
• Monitor depression symptoms closely
• May need to double sertraline dose or more (titrate based on response)
• Consider alternative antidepressant (e.g., mirtazapine, escitalopram — though all affected to some degree)
• After stopping rifampicin: gradually reduce sertraline dose back to pre-rifampicin level over 2–4 weeks (rifampicin enzyme induction wears off over ~2 weeks)
5. Alcohol
Mechanism: Pharmacodynamic interaction; additive CNS depression
Risk: Increased sedation, impaired judgment, worsening depression
Management:
• Advise patients to avoid or minimize alcohol consumption while on sertraline
• Educate that alcohol can worsen depression and reduce medication efficacy
• Not a pharmacokinetic interaction (sertraline does not significantly alter alcohol metabolism)
• Advise patients to avoid or minimize alcohol consumption while on sertraline
• Educate that alcohol can worsen depression and reduce medication efficacy
• Not a pharmacokinetic interaction (sertraline does not significantly alter alcohol metabolism)
6. Cimetidine
Mechanism: Cimetidine inhibits CYP2C19, CYP2D6, CYP3A4 → reduces sertraline clearance → increased sertraline levels
Risk: Increased SSRI side effects (nausea, diarrhea, agitation, tremor)
Management:
• Monitor for increased sertraline side effects if cimetidine started
• Consider alternative H2-blocker (ranitidine, famotidine) or PPI (no interaction)
• May need to reduce sertraline dose if significant side effects occur
• Monitor for increased sertraline side effects if cimetidine started
• Consider alternative H2-blocker (ranitidine, famotidine) or PPI (no interaction)
• May need to reduce sertraline dose if significant side effects occur
7. Digoxin
Mechanism: Unclear; possible pharmacokinetic interaction
Risk: Digoxin toxicity (though evidence conflicting; generally considered low risk)
Management:
• Monitor digoxin levels if available, or monitor clinically for digoxin toxicity (nausea, vomiting, visual changes, arrhythmias)
• Routine ECG monitoring for bradycardia, AV block
• Monitor digoxin levels if available, or monitor clinically for digoxin toxicity (nausea, vomiting, visual changes, arrhythmias)
• Routine ECG monitoring for bradycardia, AV block
8. Antipsychotics (Non-CYP2D6 Substrates)
Drugs: Olanzapine, quetiapine, haloperidol (substrate but wide therapeutic index)
Mechanism: Pharmacodynamic (additive sedation, possible additive QT prolongation with some agents)
Risk: Sedation, orthostatic hypotension; QT prolongation (especially haloperidol, quetiapine high dose)
Management:
• Can be used together (commonly combined in depression with psychotic features, bipolar depression, treatment-resistant depression)
• Monitor for sedation, orthostatic vital signs
• ECG if using haloperidol or high-dose quetiapine
• Taper antipsychotic once psychotic symptom
• Can be used together (commonly combined in depression with psychotic features, bipolar depression, treatment-resistant depression)
• Monitor for sedation, orthostatic vital signs
• ECG if using haloperidol or high-dose quetiapine
• Taper antipsychotic once psychotic symptom
Common Adverse effects
COMMON ADVERSE EFFECTS
Incidence ≥1–10%; generally mild and transient:
• Nausea (most common, especially first 2 weeks; take with food to minimize; usually resolves)
• Diarrhea / loose stools (common; usually mild; rarely requires discontinuation)
• Headache (usually mild; manage with paracetamol)
• Insomnia / sleep disturbance (take in morning to minimize; can also cause drowsiness in some patients)
• Somnolence / drowsiness (less common with sertraline than some SSRIs; take at bedtime if occurs)
• Dizziness (usually mild; advise caution with activities requiring alertness initially)
• Agitation, anxiety, nervousness (especially first 2 weeks; start with low dose in anxiety disorders to minimize; usually transient)
• Tremor (fine tremor of hands; usually mild; dose-related)
• Dry mouth (encourage hydration, sugar-free gum/candy, saliva substitutes)
• Sexual dysfunction: (20–40% incidence, often underreported)
– Delayed ejaculation / anorgasmia (most common)
– Decreased libido
– Erectile dysfunction
– Reduced genital sensitivity
– Management: Dose reduction if possible, drug holiday (skip doses on weekends — not generally recommended due to withdrawal risk), add antidote (sildenafil for ED, bupropion — not available in India; consider switching to mirtazapine or agomelatine if severe and persistent)
• Increased sweating / hyperhidrosis (especially night sweats)
• Fatigue / asthenia
• Decreased appetite / weight loss (early; can shift to weight gain with long-term use)
• Dyspepsia / indigestion
• Diarrhea / loose stools (common; usually mild; rarely requires discontinuation)
• Headache (usually mild; manage with paracetamol)
• Insomnia / sleep disturbance (take in morning to minimize; can also cause drowsiness in some patients)
• Somnolence / drowsiness (less common with sertraline than some SSRIs; take at bedtime if occurs)
• Dizziness (usually mild; advise caution with activities requiring alertness initially)
• Agitation, anxiety, nervousness (especially first 2 weeks; start with low dose in anxiety disorders to minimize; usually transient)
• Tremor (fine tremor of hands; usually mild; dose-related)
• Dry mouth (encourage hydration, sugar-free gum/candy, saliva substitutes)
• Sexual dysfunction: (20–40% incidence, often underreported)
– Delayed ejaculation / anorgasmia (most common)
– Decreased libido
– Erectile dysfunction
– Reduced genital sensitivity
– Management: Dose reduction if possible, drug holiday (skip doses on weekends — not generally recommended due to withdrawal risk), add antidote (sildenafil for ED, bupropion — not available in India; consider switching to mirtazapine or agomelatine if severe and persistent)
• Increased sweating / hyperhidrosis (especially night sweats)
• Fatigue / asthenia
• Decreased appetite / weight loss (early; can shift to weight gain with long-term use)
• Dyspepsia / indigestion
Serious Adverse effects
SERIOUS ADVERSE EFFECTS
Rare but clinically important; requires immediate action:
1. Serotonin Syndrome
Incidence: Rare; higher risk with drug combinations (MAOIs, tramadol, triptans, other serotonergic drugs) or overdose
Presentation: Triad of:
• Autonomic instability: Hyperthermia, tachycardia, labile BP, diaphoresis, mydriasis
• Neuromuscular abnormalities: Myoclonus, hyperreflexia, rigidity, tremor, clonus (especially lower extremities)
• Mental status changes: Agitation, confusion, delirium, coma
• Autonomic instability: Hyperthermia, tachycardia, labile BP, diaphoresis, mydriasis
• Neuromuscular abnormalities: Myoclonus, hyperreflexia, rigidity, tremor, clonus (especially lower extremities)
• Mental status changes: Agitation, confusion, delirium, coma
Severity: Mild (tremor, diarrhea, tachycardia) to life-threatening (hyperthermia >41°C, seizures, rhabdomyolysis, DIC, death)
Management:
• Discontinue sertraline and all serotonergic drugs immediately
• Supportive care: IV fluids, cooling, benzodiazepines (lorazepam, diazepam) for agitation/seizures
• ICU admission if severe
• Specific antidote: Cyproheptadine (serotonin antagonist) 12 mg initial dose, then 2 mg q2h until symptoms improve (max 32 mg/day) — not widely available in India; supportive care mainstay
• Discontinue sertraline and all serotonergic drugs immediately
• Supportive care: IV fluids, cooling, benzodiazepines (lorazepam, diazepam) for agitation/seizures
• ICU admission if severe
• Specific antidote: Cyproheptadine (serotonin antagonist) 12 mg initial dose, then 2 mg q2h until symptoms improve (max 32 mg/day) — not widely available in India; supportive care mainstay
2. Suicidal Ideation and Behaviour
Incidence: Black box warning (US FDA); increased risk in children, adolescents, young adults <25 years, especially first 4 weeks of treatment or after dose changes
Mechanism: "Activation syndrome" — SSRI may increase energy/motivation before improving mood, allowing suicidal ideation to be acted upon; or disinhibition effect
Risk factors: Age <25 years, previous suicide attempt, severe depression, comorbid anxiety/agitation, substance abuse, impulsivity
Management:
• Close monitoring especially weeks 1–4 and after dose changes: weekly visits or phone contact
• Involve family/caregivers in monitoring; provide emergency contact numbers
• Assess suicidality at each visit (passive ideation, active ideation, plan, intent, access to means)
• Prescribe limited quantities initially (7–14 day supply) to limit overdose potential
• If active suicidal ideation develops: Immediate psychiatric consultation, consider hospitalization, discontinue sertraline (gradually if safe to do so), consider ECT or alternative treatment
• Document risk assessment and safety plan in medical record
• Close monitoring especially weeks 1–4 and after dose changes: weekly visits or phone contact
• Involve family/caregivers in monitoring; provide emergency contact numbers
• Assess suicidality at each visit (passive ideation, active ideation, plan, intent, access to means)
• Prescribe limited quantities initially (7–14 day supply) to limit overdose potential
• If active suicidal ideation develops: Immediate psychiatric consultation, consider hospitalization, discontinue sertraline (gradually if safe to do so), consider ECT or alternative treatment
• Document risk assessment and safety plan in medical record
3. Seizures
Incidence: Rare (<0.1%); dose-related
Risk factors: History of epilepsy, structural brain lesion, metabolic disorder, alcohol/benzodiazepine withdrawal, concomitant medications lowering seizure threshold, rapid dose escalation, high doses
Management:
• Discontinue sertraline if seizure occurs and no other clear cause
• Neurologic evaluation (EEG, imaging if new-onset seizure)
• Do not rechallenge with sertraline if clear temporal relationship
• Consider alternative antidepressant with lower seizure risk (escitalopram, mirtazapine)
• Discontinue sertraline if seizure occurs and no other clear cause
• Neurologic evaluation (EEG, imaging if new-onset seizure)
• Do not rechallenge with sertraline if clear temporal relationship
• Consider alternative antidepressant with lower seizure risk (escitalopram, mirtazapine)
4. Hyponatremia / SIADH (Syndrome of Inappropriate ADH Secretion)
Incidence: 0.5–2%; much higher in elderly (up to 10%)
Mechanism: SSRIs enhance ADH release or sensitivity → water retention → dilutional hyponatremia
Risk factors: Age >65 years, female, low body weight, diuretic use (especially thiazides), baseline low sodium, first 4 weeks of treatment
Presentation: Mild (Na+ 125–135 mEq/L): asymptomatic or mild confusion, headache, nausea. Severe (Na+ <120 mEq/L): confusion, seizures, coma
Management:
• Monitor sodium at baseline, 2 weeks, 4 weeks (especially elderly)
• If hyponatremia develops:
– Mild (125–135 mEq/L), asymptomatic: Continue sertraline, fluid restriction, monitor sodium closely
– Moderate (120–125 mEq/L) or symptomatic: Discontinue sertraline, fluid restriction, specialist input (endocrinology/nephrology)
– Severe (<120 mEq/L): Discontinue sertraline, hospital admission, careful sodium correction (avoid overly rapid correction → osmotic demyelination syndrome)
• Alternative antidepressant if severe or recurrent hyponatremia: Consider mirtazapine (lower SIADH risk)
• Monitor sodium at baseline, 2 weeks, 4 weeks (especially elderly)
• If hyponatremia develops:
– Mild (125–135 mEq/L), asymptomatic: Continue sertraline, fluid restriction, monitor sodium closely
– Moderate (120–125 mEq/L) or symptomatic: Discontinue sertraline, fluid restriction, specialist input (endocrinology/nephrology)
– Severe (<120 mEq/L): Discontinue sertraline, hospital admission, careful sodium correction (avoid overly rapid correction → osmotic demyelination syndrome)
• Alternative antidepressant if severe or recurrent hyponatremia: Consider mirtazapine (lower SIADH risk)
5. QT Prolongation and Torsades de Pointes
Incidence: Very rare; sertraline has lower QT risk than citalopram/escitalopram
Risk factors: High dose (>200 mg), baseline QT prolongation, congenital long QT syndrome, electrolyte abnormalities (hypokalemia, hypomagnesemia), bradycardia, concomitant QT-prolonging drugs, female sex
Management:
• Baseline ECG if risk factors present
• Correct electrolytes (K+ >4.0 mEq/L, Mg2+ >2.0 mEq/L)
• Monitor ECG if symptoms (syncope, palpitations)
• If QTc >500 msec or increase >60 msec from baseline: Discontinue sertraline; cardiology consultation
• Alternative antidepressant: Mirtazapine (no QT effect)
• Baseline ECG if risk factors present
• Correct electrolytes (K+ >4.0 mEq/L, Mg2+ >2.0 mEq/L)
• Monitor ECG if symptoms (syncope, palpitations)
• If QTc >500 msec or increase >60 msec from baseline: Discontinue sertraline; cardiology consultation
• Alternative antidepressant: Mirtazapine (no QT effect)
6. Bleeding Events (GI, Intracranial)
Incidence: 1–2% for clinically significant GI bleeding; intracranial hemorrhage very rare (but higher with concurrent anticoagulants)
Risk factors: Age >65 years, history of GI bleeding/peptic ulcer, concurrent NSAIDs/aspirin/anticoagulants, alcohol use, H. pylori infection
Management:
• See Major/Moderate Interactions for anticoagulant/antiplatelet use
• Co-prescribe PPI if high risk
• If GI bleeding occurs: Discontinue sertraline, gastroenterology consultation, endoscopy if indicated
• Can rechallenge after healing if benefits outweigh risks and risk factors modified (add PPI, stop NSAID, etc.)
• See Major/Moderate Interactions for anticoagulant/antiplatelet use
• Co-prescribe PPI if high risk
• If GI bleeding occurs: Discontinue sertraline, gastroenterology consultation, endoscopy if indicated
• Can rechallenge after healing if benefits outweigh risks and risk factors modified (add PPI, stop NSAID, etc.)
7. Mania / Hypomania (Bipolar Switch)
Incidence: 1–2% in undiagnosed bipolar disorder; higher in bipolar I than bipolar II
Risk factors: Personal or family history of bipolar disorder, prior manic/hypomanic episode, early-onset depression (<25 years), psychotic depression, antidepressant-induced activation
Presentation: Elevated mood, decreased need for sleep, pressured speech, grandiosity, increased goal-directed activity, impulsivity, irritability
Management:
• Discontinue sertraline (or reduce to lowest effective dose)
• Start mood stabilizer (lithium, valproate) or atypical antipsychotic (quetiapine, olanzapine)
• Psychiatric consultation
• Re-evaluate diagnosis (may be bipolar disorder, not unipolar depression)
• Avoid SSRI monotherapy in bipolar disorder (use mood stabilizer ± antipsychotic; add SSRI cautiously only if needed for bipolar depression and on mood stabilizer)
• Discontinue sertraline (or reduce to lowest effective dose)
• Start mood stabilizer (lithium, valproate) or atypical antipsychotic (quetiapine, olanzapine)
• Psychiatric consultation
• Re-evaluate diagnosis (may be bipolar disorder, not unipolar depression)
• Avoid SSRI monotherapy in bipolar disorder (use mood stabilizer ± antipsychotic; add SSRI cautiously only if needed for bipolar depression and on mood stabilizer)
8. Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN)
Incidence: Extremely rare (case reports)
Presentation: Severe mucocutaneous reaction; prodrome of fever, malaise; then painful erythematous rash, bullae, mucosal involvement (oral, ocular, genital), skin sloughing
Management:
• Discontinue sertraline immediately if SJS/TEN suspected
• Emergency dermatology + ophthalmology consultation
• Hospital admission (burn unit or ICU)
• Do NOT rechallenge with sertraline or other SSRIs
• Report to pharmacovigilance (CDSCO)
• Discontinue sertraline immediately if SJS/TEN suspected
• Emergency dermatology + ophthalmology consultation
• Hospital admission (burn unit or ICU)
• Do NOT rechallenge with sertraline or other SSRIs
• Report to pharmacovigilance (CDSCO)
9. Angle-Closure Glaucoma (Acute)
Incidence: Very rare
Mechanism: SSRIs may cause pupillary dilation → angle closure in predisposed individuals (shallow anterior chamber, hyperopia)
Presentation: Sudden eye pain, blurred vision, halos around lights, headache, nausea, vomiting
Management:
• Ophthalmology emergency — immediate referral
• Stop sertraline
• Treatment: Laser iridotomy (definitive), topical medications to lower intraocular pressure
• Can resume sertraline after iridotomy if needed
• Ophthalmology emergency — immediate referral
• Stop sertraline
• Treatment: Laser iridotomy (definitive), topical medications to lower intraocular pressure
• Can resume sertraline after iridotomy if needed
10. Withdrawal Syndrome (SSRI Discontinuation Syndrome)
Incidence: 20–50% if stopped abruptly; less common with sertraline (longer half-life) than paroxetine but still occurs
Presentation: Flu-like symptoms (fatigue, myalgia, nausea), dizziness, paresthesias ("brain zaps"), insomnia, vivid dreams, irritability, anxiety, low mood (not recurrence of depression; occurs within days of stopping)
Prevention:
• Always taper sertraline when discontinuing (reduce by 25–50 mg every 1–2 weeks)
• Slower taper if on high dose or long duration
• Educate patients not to stop abruptly
• Always taper sertraline when discontinuing (reduce by 25–50 mg every 1–2 weeks)
• Slower taper if on high dose or long duration
• Educate patients not to stop abruptly
Management if occurs:
• Reinstate sertraline at previous dose (symptoms resolve within 24–48 hours)
• Then taper more slowly
• Symptomatic treatment: Fluoxetine single dose (20 mg) can alleviate symptoms due to long half-life (self-tapering effect)
• Reinstate sertraline at previous dose (symptoms resolve within 24–48 hours)
• Then taper more slowly
• Symptomatic treatment: Fluoxetine single dose (20 mg) can alleviate symptoms due to long half-life (self-tapering effect)
Monitoring requirements
MONITORING REQUIREMENTS
Baseline (Before Starting Sertraline):
Clinical assessment:
• Psychiatric history: Diagnosis (confirm depression/anxiety disorder), severity (depression rating scale: PHQ-9, HAM-D if available), previous treatments and response, duration of illness
• Suicide risk assessment (ideation, plan, intent, previous attempts, access to means, protective factors)
• Substance use history (alcohol, drugs)
• Family psychiatric history (especially bipolar disorder, suicide)
• Medical history: Cardiovascular disease, seizures, liver disease, renal disease, bleeding disorders, glaucoma
• Current medications (drug interaction check)
• Mental status examination
• Psychiatric history: Diagnosis (confirm depression/anxiety disorder), severity (depression rating scale: PHQ-9, HAM-D if available), previous treatments and response, duration of illness
• Suicide risk assessment (ideation, plan, intent, previous attempts, access to means, protective factors)
• Substance use history (alcohol, drugs)
• Family psychiatric history (especially bipolar disorder, suicide)
• Medical history: Cardiovascular disease, seizures, liver disease, renal disease, bleeding disorders, glaucoma
• Current medications (drug interaction check)
• Mental status examination
Laboratory / Investigations (selective based on risk factors):
• Serum sodium (especially if elderly, on diuretics, or baseline symptoms)
• Liver function tests if baseline liver disease suspected
• Renal function (serum creatinine, eGFR) if elderly or renal disease
• ECG if:
– Age >65 years with cardiac risk factors
– History of cardiac disease (arrhythmias, congenital long QT, recent MI)
– On QT-prolonging drugs
– Electrolyte abnormalities (hypokalemia, hypomagnesemia) → correct before starting
• Pregnancy test if woman of childbearing potential (discuss risks if positive)
• Serum sodium (especially if elderly, on diuretics, or baseline symptoms)
• Liver function tests if baseline liver disease suspected
• Renal function (serum creatinine, eGFR) if elderly or renal disease
• ECG if:
– Age >65 years with cardiac risk factors
– History of cardiac disease (arrhythmias, congenital long QT, recent MI)
– On QT-prolonging drugs
– Electrolyte abnormalities (hypokalemia, hypomagnesemia) → correct before starting
• Pregnancy test if woman of childbearing potential (discuss risks if positive)
After Initiation / Dose Change:
Week 1–2:
• Clinical review (in-person or phone contact):
– Tolerability: Nausea, diarrhea, headache, insomnia, activation/agitation
– Suicidality assessment (especially age <25 years)
– Adherence
– Reassurance that full effect takes 4–6 weeks
• Serum sodium at 2 weeks if elderly or high risk
• Clinical review (in-person or phone contact):
– Tolerability: Nausea, diarrhea, headache, insomnia, activation/agitation
– Suicidality assessment (especially age <25 years)
– Adherence
– Reassurance that full effect takes 4–6 weeks
• Serum sodium at 2 weeks if elderly or high risk
Week 4:
• Clinical review:
– Early response (25–50% improvement suggests likely full response)
– Side effects (should be improving if transient; assess sexual dysfunction proactively)
– Suicidality
• Serum sodium at 4 weeks if elderly or high risk, or if new confusion/headache
• Clinical review:
– Early response (25–50% improvement suggests likely full response)
– Side effects (should be improving if transient; assess sexual dysfunction proactively)
– Suicidality
• Serum sodium at 4 weeks if elderly or high risk, or if new confusion/headache
Week 6–8:
• Assess therapeutic response:
– Use structured tool (PHQ-9, HAM-D) to quantify improvement
– Adequate trial = 6–8 weeks at therapeutic dose (≥50 mg for depression, 100–200 mg for OCD)
– If inadequate response: Increase dose or consider switch/augmentation (psychiatry consultation)
• Side effects management
• Plan long-term therapy if responding
• Assess therapeutic response:
– Use structured tool (PHQ-9, HAM-D) to quantify improvement
– Adequate trial = 6–8 weeks at therapeutic dose (≥50 mg for depression, 100–200 mg for OCD)
– If inadequate response: Increase dose or consider switch/augmentation (psychiatry consultation)
• Side effects management
• Plan long-term therapy if responding
Long-term Monitoring (Chronic Use):
Every 1–3 months initially, then every 3–6 months once stable:
• Clinical response and symptom monitoring (PHQ-9 or similar)
• Functional status (return to work, social activities, relationships)
• Adherence
• Side effects:
– Sexual dysfunction (assess at every visit; often not volunteered)
– Weight changes (can cause weight gain long-term in some patients; monitor BMI)
– Emotional blunting / apathy (anhedonia despite depression remission — "SSRI-induced apathy syndrome"; may need dose reduction or switch)
• Serum sodium annually if elderly, or if new symptoms suggestive of hyponatremia
• Clinical response and symptom monitoring (PHQ-9 or similar)
• Functional status (return to work, social activities, relationships)
• Adherence
• Side effects:
– Sexual dysfunction (assess at every visit; often not volunteered)
– Weight changes (can cause weight gain long-term in some patients; monitor BMI)
– Emotional blunting / apathy (anhedonia despite depression remission — "SSRI-induced apathy syndrome"; may need dose reduction or switch)
• Serum sodium annually if elderly, or if new symptoms suggestive of hyponatremia
Before discontinuation (when appropriate):
• Ensure sustained remission (≥6–12 months symptom-free for first episode; longer for recurrent)
• Psychosocial stability (no major stressors, good support system)
• Patient agreement and understanding of relapse risk
• Gradual taper plan (reduce by 25–50 mg every 1–2 weeks; slower if high dose or long duration)
• Close monitoring during taper and first 6 months after discontinuation (highest relapse risk)
• Ensure sustained remission (≥6–12 months symptom-free for first episode; longer for recurrent)
• Psychosocial stability (no major stressors, good support system)
• Patient agreement and understanding of relapse risk
• Gradual taper plan (reduce by 25–50 mg every 1–2 weeks; slower if high dose or long duration)
• Close monitoring during taper and first 6 months after discontinuation (highest relapse risk)
No routine monitoring required:
• Liver function tests (unless baseline liver disease or new hepatic symptoms)
• Renal function (unless baseline renal disease or elderly with decline in GFR)
• ECG (unless baseline indication or new cardiac symptoms)
• Drug levels (sertraline therapeutic drug monitoring not routinely available or recommended in India)
• Liver function tests (unless baseline liver disease or new hepatic symptoms)
• Renal function (unless baseline renal disease or elderly with decline in GFR)
• ECG (unless baseline indication or new cardiac symptoms)
• Drug levels (sertraline therapeutic drug monitoring not routinely available or recommended in India)
Brands in India
BRANDS AVAILABLE IN INDIA
Common brands (sertraline hydrochloride):
• Zoloft (Pfizer) — innovator brand; less commonly available/prescribed in India
• Daxid (Abbott India / Pfizer marketed previously)
• Serlift (Torrent Pharmaceuticals) — widely available
• Zosert (Sun Pharmaceutical)
• Sertafine (Intas Pharmaceuticals)
• Sertral (Unichem Laboratories)
• Serta (Intas)
• Sertima (Lupin)
• Asentra (Ranbaxy / Sun Pharma)
• Serenata (Cipla)
• Daxid (Abbott India / Pfizer marketed previously)
• Serlift (Torrent Pharmaceuticals) — widely available
• Zosert (Sun Pharmaceutical)
• Sertafine (Intas Pharmaceuticals)
• Sertral (Unichem Laboratories)
• Serta (Intas)
• Sertima (Lupin)
• Asentra (Ranbaxy / Sun Pharma)
• Serenata (Cipla)
Fixed-dose combinations (FDCs):
• Sertraline + Clonazepam (various brands):
– Example: Zosert-Plus (sertraline 50 mg + clonazepam 0.5 mg)
– Not first-line; used in some Indian psychiatric practice for comorbid anxiety/insomnia
– Concerns: Benzodiazepine dependence risk; prefer sertraline monotherapy with short-term benzodiazepine if needed, then taper benzodiazepine
– CDSCO approval status: Many sertraline FDCs with benzodiazepines are approved, but rationality debated
– Example: Zosert-Plus (sertraline 50 mg + clonazepam 0.5 mg)
– Not first-line; used in some Indian psychiatric practice for comorbid anxiety/insomnia
– Concerns: Benzodiazepine dependence risk; prefer sertraline monotherapy with short-term benzodiazepine if needed, then taper benzodiazepine
– CDSCO approval status: Many sertraline FDCs with benzodiazepines are approved, but rationality debated
Note on FDCs: Indian guidelines and global best practice recommend monotherapy with sertraline for depression/anxiety disorders. Benzodiazepines may be added short-term for severe anxiety but should be separate prescriptions (not FDC) to allow independent titration and tapering.
Price range (INR)
PRICE RANGE (INR)
Approximate retail prices (private pharmacy; as of 2024; varies by brand and region):
| Formulation | Brand Example | Price Range (INR) | Per Tablet Cost |
|---|---|---|---|
|
25 mg tablet (10 tablets)
|
Serlift, Zosert | ₹25–50 | ₹2.5–5 |
|
50 mg tablet (10 tablets)
|
Serlift, Zosert | ₹30–80 | ₹3–8 |
|
100 mg tablet (10 tablets)
|
Serlift, Zosert | ₹50–120 | ₹5–12 |
NLEM status:
• Sertraline is NOT included in NLEM 2022 (National List of Essential Medicines)
• NOT under NPPA price control (National Pharmaceutical Pricing Authority ceiling price not applicable)
• Pricing is market-driven; varies significantly between brands
• Sertraline is NOT included in NLEM 2022 (National List of Essential Medicines)
• NOT under NPPA price control (National Pharmaceutical Pricing Authority ceiling price not applicable)
• Pricing is market-driven; varies significantly between brands
Government supply:
• Limited availability in government hospitals and mental health institutions
• More commonly available: Fluoxetine, escitalopram (NLEM-listed antidepressants)
• Sertraline may be available in tertiary psychiatric hospitals (NIMHANS, state mental hospitals) but not reliably in primary health centers
• Limited availability in government hospitals and mental health institutions
• More commonly available: Fluoxetine, escitalopram (NLEM-listed antidepressants)
• Sertraline may be available in tertiary psychiatric hospitals (NIMHANS, state mental hospitals) but not reliably in primary health centers
Generic vs. branded:
• Generic sertraline significantly cheaper (₹2–3 per 50 mg tablet)
• Branded versions ₹5–8 per 50 mg tablet
• Bioequivalence generally acceptable for SSRIs; generic substitution reasonable for cost savings
• Generic sertraline significantly cheaper (₹2–3 per 50 mg tablet)
• Branded versions ₹5–8 per 50 mg tablet
• Bioequivalence generally acceptable for SSRIs; generic substitution reasonable for cost savings
Out-of-pocket cost for typical treatment:
• 50 mg/day for 1 month: ₹90–240 (branded), ₹60–90 (generic)
• 100 mg/day for 1 month: ₹150–360 (branded), ₹90–120 (generic)
• Long-term therapy (6–12 months): ₹540–4320 depending on dose and brand — significant burden for low-income patients; consider generic or switch to fluoxetine (NLEM-listed, cheaper) if cost barrier
• 50 mg/day for 1 month: ₹90–240 (branded), ₹60–90 (generic)
• 100 mg/day for 1 month: ₹150–360 (branded), ₹90–120 (generic)
• Long-term therapy (6–12 months): ₹540–4320 depending on dose and brand — significant burden for low-income patients; consider generic or switch to fluoxetine (NLEM-listed, cheaper) if cost barrier
Clinical pearls
CLINICAL PEARLS
1. Sertraline is preferred SSRI for cardiac patients
• Lower risk of QT prolongation compared to citalopram/escitalopram
• Can be used post-MI (depression common post-MI and worsens cardiac outcomes; SSRIs safe and beneficial)
• SADHART trial (Sertraline Antidepressant Heart Attack Randomized Trial): Demonstrated safety in post-MI patients
• Caution still needed with drug interactions (beta-blockers metabolized by CYP2D6 like metoprolol)
• Can be used post-MI (depression common post-MI and worsens cardiac outcomes; SSRIs safe and beneficial)
• SADHART trial (Sertraline Antidepressant Heart Attack Randomized Trial): Demonstrated safety in post-MI patients
• Caution still needed with drug interactions (beta-blockers metabolized by CYP2D6 like metoprolol)
2. Start low in anxiety disorders to avoid activation
• Panic disorder, social anxiety: Start 25 mg/day × 1 week, then increase to 50 mg
• Initial anxiety/agitation ("jitteriness syndrome") occurs in 10–20% of anxious patients starting SSRI
• Usually transient (1–2 weeks) but can be distressing and lead to discontinuation
• Short-term benzodiazepine (clonazepam 0.25–0.5 mg BD for 2 weeks) can bridge this period, then taper as SSRI effect kicks in
• Educate patient in advance about possible initial worsening before improvement
• Initial anxiety/agitation ("jitteriness syndrome") occurs in 10–20% of anxious patients starting SSRI
• Usually transient (1–2 weeks) but can be distressing and lead to discontinuation
• Short-term benzodiazepine (clonazepam 0.25–0.5 mg BD for 2 weeks) can bridge this period, then taper as SSRI effect kicks in
• Educate patient in advance about possible initial worsening before improvement
3. Timing of dose: morning vs. evening — individualize
• Standard recommendation: Morning (to minimize insomnia risk)
• If patient experiences sedation: Switch to bedtime dosing
• If insomnia persists despite morning dosing: Address sleep hygiene, consider adding low-dose mirtazapine at night (also augments antidepressant effect) or trazodone (not available in India as monotherapy; combination product with sertraline banned)
• Consistent timing more important than specific time of day
• If patient experiences sedation: Switch to bedtime dosing
• If insomnia persists despite morning dosing: Address sleep hygiene, consider adding low-dose mirtazapine at night (also augments antidepressant effect) or trazodone (not available in India as monotherapy; combination product with sertraline banned)
• Consistent timing more important than specific time of day
4. Sexual dysfunction is dose-related and common — address proactively
• Incidence: 20–40% (likely underestimated; patients often don't volunteer)
• Ask specifically at each visit: "Any changes in sexual function, interest, or satisfaction?"
• Management options:
– Wait and see: Sometimes improves after 2–3 months (tolerance develops)
– Dose reduction: If clinically stable, try reducing from 100 mg to 50 mg
– Drug holiday: Skip sertraline on weekends (not recommended — withdrawal risk, inconsistent dosing)
– Add PDE-5 inhibitor: Sildenafil 25–50 mg PRN for erectile dysfunction (effective; safe combination)
– Switch antidepressant: Mirtazapine (lower sexual dysfunction; weight gain risk), bupropion (NOT available in India), agomelatine (available in India, expensive)
• Don't ignore: Sexual dysfunction is major cause of treatment discontinuation and relapse
• Ask specifically at each visit: "Any changes in sexual function, interest, or satisfaction?"
• Management options:
– Wait and see: Sometimes improves after 2–3 months (tolerance develops)
– Dose reduction: If clinically stable, try reducing from 100 mg to 50 mg
– Drug holiday: Skip sertraline on weekends (not recommended — withdrawal risk, inconsistent dosing)
– Add PDE-5 inhibitor: Sildenafil 25–50 mg PRN for erectile dysfunction (effective; safe combination)
– Switch antidepressant: Mirtazapine (lower sexual dysfunction; weight gain risk), bupropion (NOT available in India), agomelatine (available in India, expensive)
• Don't ignore: Sexual dysfunction is major cause of treatment discontinuation and relapse
5. Hyponatremia risk higher in elderly — monitor sodium
• Routine sodium check at weeks 2 and 4 in patients >65 years, especially if on diuretics
• Symptoms often non-specific (confusion, falls, weakness) and may be attributed to depression or aging
• Low threshold to check sodium if any new confusion, lethargy, or falls in elderly on sertraline
• If severe or recurrent, switch to mirtazapine (much lower SIADH risk)
• Symptoms often non-specific (confusion, falls, weakness) and may be attributed to depression or aging
• Low threshold to check sodium if any new confusion, lethargy, or falls in elderly on sertraline
• If severe or recurrent, switch to mirtazapine (much lower SIADH risk)
6. Pregnancy and lactation: reassure and continue if needed
• Sertraline is one of best-studied and safest SSRIs in pregnancy
• Untreated maternal depression has clear fetal/neonatal risks (poor prenatal care, preterm birth, low birth weight, postpartum depression, impaired bonding)
• Benefits of treatment usually outweigh small risks
• Do not discontinue abruptly if patient becomes pregnant — gradual taper if stopping, or continue if moderate-severe depression
• Lactation: Very low infant exposure; preferred SSRI for breastfeeding mothers
• Coordinate care with obstetrician; document shared decision-making
• Untreated maternal depression has clear fetal/neonatal risks (poor prenatal care, preterm birth, low birth weight, postpartum depression, impaired bonding)
• Benefits of treatment usually outweigh small risks
• Do not discontinue abruptly if patient becomes pregnant — gradual taper if stopping, or continue if moderate-severe depression
• Lactation: Very low infant exposure; preferred SSRI for breastfeeding mothers
• Coordinate care with obstetrician; document shared decision-making
7. Always taper when discontinuing — even if patient feels well
• Never stop abruptly (SSRI discontinuation syndrome common)
• Taper slowly: Reduce by 25–50 mg every 1–2 weeks
• Slower taper if on high dose (≥150 mg) or long duration (>1 year)
• Educate patient: Symptoms like dizziness, "brain zaps," flu-like symptoms are withdrawal (not relapse, not addiction) and resolve with slower taper
• If patient stops abruptly and develops withdrawal: Reinstate previous dose (symptoms resolve in 1–2 days), then taper properly
• Taper slowly: Reduce by 25–50 mg every 1–2 weeks
• Slower taper if on high dose (≥150 mg) or long duration (>1 year)
• Educate patient: Symptoms like dizziness, "brain zaps," flu-like symptoms are withdrawal (not relapse, not addiction) and resolve with slower taper
• If patient stops abruptly and develops withdrawal: Reinstate previous dose (symptoms resolve in 1–2 days), then taper properly
8. OCD requires higher doses and longer trials than depression
• Usual effective dose for OCD: 100–200 mg/day (vs. 50–100 mg for depression)
• Adequate trial: 10–12 weeks at 150–200 mg/day before declaring treatment failure (vs. 6–8 weeks for depression)
• Response often partial (30–50% symptom reduction); combine with cognitive-behavioural therapy (CBT) — exposure and response prevention (ERP) for optimal outcomes
• If inadequate response after adequate trial: Augment with antipsychotic (risperidone 1–2 mg, aripiprazole 5–10 mg) or switch to clomipramine (TCA; more effective for OCD but more side effects)
• Adequate trial: 10–12 weeks at 150–200 mg/day before declaring treatment failure (vs. 6–8 weeks for depression)
• Response often partial (30–50% symptom reduction); combine with cognitive-behavioural therapy (CBT) — exposure and response prevention (ERP) for optimal outcomes
• If inadequate response after adequate trial: Augment with antipsychotic (risperidone 1–2 mg, aripiprazole 5–10 mg) or switch to clomipramine (TCA; more effective for OCD but more side effects)
Version
RxIndia v0.2 — 18 May 2025
Reference
REFERENCES
- CDSCO (Central Drugs Standard Control Organisation):
• Sertraline hydrochloride product inserts (various manufacturers registered in India)
• Approved indications: Major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder - Indian Pharmacopoeia 2018 — Sertraline Hydrochloride monograph
- NLEM 2022 (National List of Essential Medicines) — Ministry of Health & Family Welfare, Government of India
• Note: Sertraline NOT included in NLEM 2022; fluoxetine and escitalopram are listed SSRIs - API Textbook of Medicine, 11th Edition — Psychiatry section: Depression, anxiety disorders, OCD management
- AIIMS Psychiatry Protocols — Department of Psychiatry, All India Institute of Medical Sciences, New Delhi
• Management of depression, anxiety disorders, OCD
• SSRI use in special populations - Indian Psychiatric Society (IPS) Guidelines:
• Clinical Practice Guidelines for Management of Depression (2017)
• Use of antidepressants in pregnancy and lactation - ICMR (Indian Council of Medical Research):
• National Mental Health Programme guidelines
• Standard Treatment Workflows for depression - Goodman & Gilman's The Pharmacological Basis of Therapeutics, 13th Edition — Antidepressants, SSRIs pharmacology
- Harrison's Principles of Internal Medicine, 21st Edition — Mental health disorders, depression and anxiety management
- International Guidelines (for context, off-label uses marked clearly):
• NICE (UK) Guidelines: Depression in adults, OCD, PTSD
• American Psychiatric Association (APA) Practice Guidelines
• SADHART Trial (Sertraline Antidepressant Heart Attack Randomized Trial) — Glassman et al., JAMA 2002 — safety in post-MI depression - LactMed (Drugs and Lactation Database) — NIH; sertraline compatibility with breastfeeding (supportive reference; India-specific data prioritized)
- Pharmacovigilance Programme of India (PvPI) — adverse event reporting for sertraline
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.